Form 4: Protagonist Therapeutics Director Receives Stock and Options Grant

Sarah A. O'Dowd, a director at Protagonist Therapeutics, received a grant of restricted stock units and stock options on January 2, 2025.

Summary

• Sarah A. O'Dowd, a director at Protagonist Therapeutics, was granted 5,130 restricted stock units and options to purchase 6,584 shares of common stock on January 2, 2025.
• The restricted stock units will vest in full on January 15, 2026, contingent on continued service to the company.
• The stock options vest in 12 equal monthly installments starting January 2, 2025, also contingent on continued service.
• The exercise price for the stock options is $38.98 per share.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of equity compensation, which is generally viewed positively as it aligns the interests of management with shareholders. There are no negative implications.

Positives

• The grant of stock and options aligns the director's interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment from the director.

Risks

• The value of the stock options is dependent on the future performance of the company's stock price.
• The vesting of both the stock units and options is contingent on continued service, which could be impacted by unforeseen circumstances.

Future Outlook

The vesting of the stock and options is contingent on continued service, suggesting an expectation of ongoing contributions from the director.

Industry Context

Equity grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are standard compensation practices for directors in publicly traded biotech companies.
• The vesting schedules are typical, with time-based vesting to encourage long-term commitment.
• The exercise price of $38.98 is relevant to the current market price of the stock at the time of the grant, which is not specified in the document.

Stakeholder Impact

• The equity grants align the director's interests with those of shareholders, potentially leading to increased value.
• The vesting schedule encourages the director's continued service, which benefits the company and its stakeholders.

Key Dates

Keywords

stock options, restricted stock units, equity compensation, director, Protagonist Therapeutics, PTGX, vesting